Conditions of Awards

1. There is no provision for Cures Within Reach (CWR) to fund overhead or indirect expenses for its portion of an award. In limited situations, CWR may agree that the Research Partner’s matching funds can partially include limited overhead when CWR determines it is critical to the success of the project. Up to 10% of any approved project budget may be used to support direct project administrative costs.

2. CWR only funds Principal Investigator (PI) or Co-Investigator (CI) salary and/or fringe benefits when the institution requires and verifies that the funding for the portion of time expended by the PI/CI must come through the CWR/CureAccelerator grant, AND when the PI/CI time devoted to the grant is not already funded through a separate funding source, such as an annual full-time salary or a combination of other grants plus salary that cover 100% or more of the PI's/CI’s time or compensation. PIs/CIs who have their salary included in the grant budget must be directly involved in the research, and can only be funded during the time when they are directly involved. Often, fully funded senior PIs devote a portion of their time to working on a grant, and/or to supervising CIs or staff on the grant. In these cases, it is acceptable to show that percentage of time allocated, but there should be $0 salary amount for these PIs in the budget.

3. While all CWR and CureAccelerator grants require a 20% co-fund by the institution or company sponsoring the research, "Double Dipping" or an overlap in funding of the 80% of the grant funded by CWR is not allowed, and CWR may terminate funding or reduce funding in the event that a grant with identical or even similar specific aims is funded by another funder. While CWR encourages applicants to submit the same grant to multiple funders for the purposes of obtaining funding, if the grant is fully or partially funded another funder, then it is the applicant’s responsibility to notify CWR so CWR can decide how to proceed. Similarly, if alternate funding is obtained after the award of a CWR grant is made and the grantee chooses the alternative funding, CWR must be notified and the CWR award will be modified or terminated.

4. Equipment costs over $5,000.00 are generally not covered expenses, except in cases where the equipment is unavailable at the research location and the failure to obtain the equipment will impair or significantly delay the outcome of research. Under certain conditions, CWR may provide funding for the purchase of this scientific equipment (defined as durable goods that cost in excess of $5,000.00) for use in active CWR-supported research grants. Requests for the purchase of such equipment are considered on a case-by-case basis and CWR reserves the right to property ownership of all equipment purchased with CWR funds. Following the termination of a CWR grant, CWR retains the right to transfer the property to another CWR grantee or institution. Equipment purchased with CWR funds is to remain under the control of the CWR grantee, when such individual transfers to another academic institution occur. If your grant request includes equipment, please investigate whether reconditioned and/or used equipment can be substituted.

5. CWR typically covers limited travel and meetings only for multi-year research projects, and then only when necessary to insure the success of the project or to present a paper at a
meeting where the presentation increases the likelihood that others will use the data to use the results of the research in clinical practice or further research to accelerate the search for a cure.

6. A standardized finance summary of expenses relative to the disbursement of this grant must be submitted semi-annually for the duration of the CWR-funded portion of the research project, and within 45 days after the end of the CWR-funded portion of the research project. Current and future funding is contingent upon receipt of periodic Financial Reports, as well as acceptable periodic Project Reports (see Condition #10 below). Subsequent funding payments will be contingent upon submission of a satisfactory Financial Reports as judged by CWR staff, Advisory Boards and/or other experts.

7. Unexpended funds are to be returned to CWR along with the standardized Financial Report required by Condition #6 above. Re-allocation of funding within the grant greater than 10% for approved budget line items requires prior CWR authorization. Re-allocation of funding to costs outside the grant is not allowed. Requests for permission to carry over budget balances to a subsequent grant period will be reviewed on a case-by-case basis and must be approved in advance of such re-allocation. A justification citing how the carry over was incurred and how the funds are expected to be spent must accompany all carry over requests. If a request for carry over is rejected, CWR may either request the return of the unused funds or, alternatively, future (or current) funding for a different Research Project at Research Partner will be reduced by the carry over amount.

8. Income earned between receipt of funds and their expenditure for the purpose so designated must be applied directly to this grant.

9. The CWR CureAccelerator Repurposing Research Co-Sponsorship Agreement must be agreed to and signed by an authorized institutional officer and returned to CWR. A copy of the approval by the appropriate institutional review committee for use of human or animal subjects must be forwarded to CWR, as well as the final Research Project protocol and any FDA approval or documentation. If appropriate, CWR will establish a mutually acceptable intellectual property agreement with the Research Partner prior to the commencement of the project.

10. Project Reports must be submitted semi-annually for the duration of the CWR-funded portion of the grant period, with a Final Project Report and Final Financial Report at the end of the grant. These will follow a CWR standardized format, which will be provided to the grantee and will include key research accomplishments, reportable outcomes, and challenges or changes to the Research Roadmap. Subsequent funding payments will be contingent upon submission of a satisfactory Project Report as judged by the CWR staff, Scientific Advisory Board and/or other scientific experts. The final Financial Report must include documentation of the full Institution 20% Cost Share in order for the CWR Final Payment to be paid in full.

11. CWR must be notified immediately of any significant personnel change.

12. All publications and presentations resulting, in whole or in part, from the work accomplished through this grant must credit support from “Cures Within Reach” and CureAccelerator®, including logos when feasible, and CWR may request additional credit be given to our funding partners. Additional names may be provided during the Research Project if new funding partners contribute to the funding partnership. An electronic copy and two print copies of each publication should be submitted to CWR as soon as each are available. It is the responsibility of the Research Partner and the PI to insure the acknowledgment is provided, and Research Partner and the PI will do everything reasonable to resolve any errors with publishers or websites where acknowledgments are in error or not made.
13. It is expected that resources (e.g., probes, vectors, DNA sequence, cloned genes, antibodies, transgenic animals, etc.) and knowledge, developed with full or partial support of CWR and reported in a scientific or other publication, be shared upon request with legitimate investigators, clinicians, patients or others in a generous and timely fashion in order to advance the collaborative goals of CWR and our funding partners.

14. CWR frequently solicits funds specifically designated for a particular research project. It is critical to involve the funders with the researchers and institutions. We will carefully manage these contacts to make them a positive experience for all parties. Researchers and institution partners agree to make themselves reasonably available to accommodate these funder face-face, e-mail, and telephone contacts, and to otherwise support CWR funder solicitation effort.

15. CWR is not responsible for any claims, judgments, awards, damages, settlements, intentional acts, willful acts, negligence, or malpractice arising from the research or investigation related to this award. The investigator’s institution must acknowledge responsibility for the conduct of research or investigations related to this award, and release CWR, its staff, Board, and funders from all claims of liability that may arise from the conduct of research or investigations related to this award resulting from any act or omission on the part of the institution, its employees, agents, or representatives.